VALTREX Drug Patent Profile
✉ Email this page to a colleague
When do Valtrex patents expire, and what generic alternatives are available?
Valtrex is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in VALTREX is valacyclovir hydrochloride. There are twenty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the valacyclovir hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valtrex
A generic version of VALTREX was approved as valacyclovir hydrochloride by SUN PHARM INDS LTD on January 31st, 2007.
Summary for VALTREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 54 |
| Patent Applications: | 1,379 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VALTREX |
| What excipients (inactive ingredients) are in VALTREX? | VALTREX excipients list |
| DailyMed Link: | VALTREX at DailyMed |
US Patents and Regulatory Information for VALTREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-002 | Jun 23, 1995 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-001 | Jun 23, 1995 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VALTREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-002 | Jun 23, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-002 | Jun 23, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-001 | Jun 23, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-002 | Jun 23, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| Glaxosmithkline | VALTREX | valacyclovir hydrochloride | TABLET;ORAL | 020487-001 | Jun 23, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VALTREX
See the table below for patents covering VALTREX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1340084 | ESTERS DE 9-(HYDROXETHOXYMETHYL)GUANINE POSSEDANT DES PROPRIETES ANTIVIRALES (ESTERS OF 9-(2-HYDROXYETHOXYMETHYL)GUANINE HAVING ANTIVIRAL PROPERTIES) | ⤷ Try a Trial |
| Singapore | 26346 | ⤷ Try a Trial | |
| Japan | H0662623 | ⤷ Try a Trial | |
| Cyprus | 2182 | ⤷ Try a Trial | |
| Czech Republic | 9702294 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VALTREX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0077460 | SPC/GB95/020 | United Kingdom | ⤷ Try a Trial | SPC/GB95/020:, EXPIRES: 20070907 |
| 0308065 | 97C0015 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VALACICLOVIR HYDROCHLORID; NAT. REGISTRATION NO/DATE: 725 IS 144 F 3 19970219; FIRST REGISTRATION: IE PA 17/111/1 19941220 |
| 0077460 | 97C0035 | Belgium | ⤷ Try a Trial | PRODUCT NAME: VALACICLOVIR; NAT REG. NO/DATE: 725 IS 144 F 3; FIRST REG.: IE PA 17/111/1 19941212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
